Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Eli Lilly & Co.

LLY

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Last trade $1,405.65
Day change -$26.02 (-1.82%)
Day range $1,402.39 – $1,439.03
Volume 1,542,033
Market cap $1.28T

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.28T
Price / earnings
46.24×
Price / book
31.67×
Price / sales
14.75×
EV / sales
15.27×
EV / EBITDA
28.39×

Profitability

Earnings per share
$30.96
Return on assets
18.63%
Return on equity
68.49%
Dividend yield
0.47%

Liquidity and leverage

Debt / equity
1.23×
Current ratio
1.39×
Quick ratio
1×
Cash ratio
0.1×

Cash flow

Price / cash flow
41.61×
Price / free cash flow
64.86×
Free cash flow
$19.66B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LLY, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$24.4B$22.97B$19.8B$19.29B$17.6B$15.56B$12.73B$13.53B
Cost of revenue$3.93B$3.27B$3.58B$3.37B$3.01B$2.45B$2.23B$2.4B
Gross profit$20.46B$19.71B$16.22B$15.92B$14.59B$13.11B$10.5B$11.13B
Selling, general and administrative$3.13B$3.43B$2.93B$3.13B$2.74B$2.75B$2.47B$2.42B
Research and development$4.25B$3.82B$3.51B$3.8B$3.47B$3.34B$2.73B$3.02B
Total operating expenses$11.86B$10.73B$7.31B$7.55B$7.23B$6.24B$6.81B$5.98B
Operating income$8.61B$8.98B$8.92B$8.37B$7.37B$6.87B$3.7B$5.15B
Interest expense$0$345M$0$0$0$249M$0$0
Income before taxes$8.41B$9.25B$8.85B$8.27B$7.23B$6.78B$3.46B$5.04B
Income taxes$1.96B$2.15B$1.45B$1.63B$1.65B$1.12B$697M$628.5M
Net income$6.45B$7.1B$7.4B$6.64B$5.58B$5.66B$2.76B$4.41B
Net income attributable to common shareholders$6.45B$7.1B$7.4B$6.64B$5.58B$5.66B$2.76B$4.41B
EBITDA$13.64B$12.99B$10.29B$9.57B$8.86B$7.5B$5.77B$6.17B
Basic earnings per share$7.23$7.95$8.27$7.41$6.22$6.30$3.07$4.90
Diluted earnings per share$7.22$7.94$8.26$7.39$6.21$6.29$3.06$4.88

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

AASM releases roadmap to improve women’s sleep health

The American Academy of Sleep Medicine released a comprehensive report and multiyear roadmap to improve women's sleep health, identifying priority areas including fertility, pregnancy, postpartum health, menopausal transitions, and sleep disorders. The report highlights gaps in research, clinical care, and policy, calling for increased clinical trial representation, research funding, and tailored interventions for women.

GlobeNewswire Inc.

Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035

The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.

Zacks Investment Research

AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?

AstraZeneca reported Q3 2026 revenues of $16.21 billion (up 7% YoY) and core EPS of $2.79, beating consensus estimates. Strong oncology sales growth (16% to $21.9B) and new drug launches support the company's $80 billion 2030 revenue target. However, generic erosion of mature drugs, recent pipeline failures, and China market uncertainties create headwinds. The company maintains mid-to-high single-digit revenue growth guidance for 2026.

Zacks Investment Research

J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts

Johnson & Johnson announced a $2.2 billion acquisition of clinical-stage biotech Ollin Biosciences to expand its ophthalmology pipeline with OLN324, a phase III bispecific antibody for retinal diseases. Blackstone will fund $750 million of the phase III development. This acquisition is part of J&J's broader strategy of pursuing strategic M&A to strengthen its Innovative Medicine and MedTech businesses, following recent acquisitions of Firefly Bio, Intra-Cellular Therapies, Shockwave Medical, and Abiomed.

Zacks Investment Research

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

The Fidelity MSCI Health Care Index ETF (FHLC) is a passively managed healthcare sector ETF with $4.08 billion in assets and a low 0.08% expense ratio. Year-to-date performance is up 21.32%, with top holdings including Eli Lilly, Johnson & Johnson, and Abbvie. The ETF carries a Zacks ETF Rank of 3 (Hold) and offers medium-risk diversified exposure to 348 healthcare companies.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Nov 13, 2026$1.73Dec 10, 2026recurring
Aug 14, 2026$1.73Sep 10, 2026recurring
May 15, 2026$1.73Jun 10, 2026recurring
Feb 13, 2026$1.73Mar 10, 2026recurring
Nov 14, 2025$1.50Dec 10, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.